Epidermolysis bullosa refers to a group of rare medical conditions that result in easy blistering of the skin and mucous membranes. Epidermolysis bullosa conditions range from mild to severe based on the extent of blistering and other medical problems that occur. Products associated with the epidermolysis bullosa market include topical antibiotics, oral antibiotics, pain medications, bandages, compression garments and others. Regular dressing changes are required to prevent infection as wounds take a long time to heal. The global epidermolysis bullosa market has witnessed significant advancements with the development of innovative therapies targeted towards correcting genetic defects causing skin fragility. These new therapies include gene therapy, cell therapy and protein replacement therapies offering the potential for long term wound healing. The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the epidermolysis bullosa market is the significant research and development in gene therapy. There are number of gene therapy candidates currently under clinical trials which are aimed at correcting genetic mutations responsible for causing skin fragility. For example, Amryt Pharma is developing AP-001, an ointment containing plasmid DNA encoding a collagen VII (C7) gene which has potential as a topical gene therapy. Another important trend is the development of cell based therapies. Scientists are working on culturing epidermal stem cells from patient’s own skin and transplanting them onto wounds to regenerate the epidermal layer. Companies like Holostem have made significant strides in this area. Rising investment from pharmaceutical companies as well as venture capital firms into innovative research is expected to fast track the development of disease modifying therapies for epidermolysis bullosa over the forecast period.
Threat of new entrants: Low barrier of entry for new competitors as the market is still in developing phase. However, established players have significant brand recognition and resources which deter new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative treatment options. However, lack of cure drives patients to seek the best available treatment.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the specialized nature of ingredients and materials required to develop Epidermolysis Bullosa treatments. Established suppliers can influence prices to some extent.
Threat of new substitutes: Threat of substitution is low as there is no cure yet for Epidermolysis Bullosa. Existing treatment options mainly focus on symptom management.
Competitive rivalry: Intense competition between existing players to gain higher market share. Companies compete on product quality, innovation, and clinical trial results.
The global Epidermolysis Bullosa market is expected to witness high growth.
Regional analysis: North America holds the highest share in the global Epidermolysis Bullosa market majorly due to developed healthcare infrastructure, rising awareness about rare diseases, and growing research activities for treatment developments in the region.
Key players: Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma’s candidates, Oleogel-S10 and FILSUVEZ, are undergoing clinical trials for Epidermolysis Bullosa treatment. Abeona Therapeutics’ clinical program, EB-101, has also shown promising results for EB patients.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it